The Neurosurgery Signal — Signal, Not Noise

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1056/NEJMoa1308573

PMID

24552317

PICO

Population

Adults with centrally confirmed newly diagnosed glioblastoma

Intervention

Radiotherapy (60 Gy) plus daily temozolomide with bevacizumab added during week 4 of radiotherapy and continued for up to 12 maintenance cycles

Comparator

Radiotherapy (60 Gy) plus daily temozolomide with placebo added during week 4 of radiotherapy and continued for up to 12 maintenance cycles

Outcomes

Overall survival, progression-free survival, toxicity, quality of life, neurocognitive function

Design

Type

Randomized controlled trial

Randomized

Yes

Multicenter

Yes

Blinded

double-blind

Follow-up

Until death or study completion

Primary endpoint

Overall survival (co-primary with progression-free survival)

Secondary endpoints

Progression-free survival
Toxicity rates
Quality of life
Neurocognitive function

Practice impact

What this means

This phase III RCT tested adding bevacizumab to standard temozolomide/radiotherapy for newly diagnosed GBM. While PFS improved from 7.3 to 10.7 months, overall survival was unchanged (15.7 vs 16.1 months). Bevacizumab increased toxicity and worsened quality of life. First-line bevacizumab should not be used outside clinical trials.

Bottom line

First-line bevacizumab added to standard chemoradiation does not improve overall survival in newly diagnosed glioblastoma and worsens quality of life.

Strength of evidence

high

Recommendation

do not change

Why it matters

No OS benefit (HR 1.13)
PFS improvement did not meet prespecified target
Increased toxicity and worse patient-reported outcomes

What would change my mind

Subgroup analysis showing OS benefit in molecularly defined populations
Long-term follow-up demonstrating delayed survival advantage
Different dosing or scheduling regimen showing benefit with acceptable toxicity

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Low: randomized, double-blind, placebo-controlled design with central confirmation of diagnosis

Confounding

Well-balanced baseline characteristics; treatment assignment was blinded

Missing data

Not explicitly detailed in excerpt; analysis appears intention-to-treat

Multiplicity

Two co-primary endpoints (OS and PFS) with prespecified statistical targets

Notes

Designed to detect 25% reduction in death risk and 30% reduction in progression/death risk

Stats check

NNT

Not applicable: no survival benefit

Effect sizes

HR for death 1.13 (bevacizumab vs placebo)
HR for progression or death 0.79 (bevacizumab vs placebo)

Absolute effects

Median OS: 15.7 months (bevacizumab) vs 16.1 months (placebo)
Median PFS: 10.7 months (bevacizumab) vs 7.3 months (placebo)

Concerns

PFS improvement did not reach prespecified 30% reduction target
Increased symptom burden and worse QOL with bevacizumab

External validity

Who it applies to

Adults with newly diagnosed glioblastoma eligible for standard chemoradiation

Who it does not

Patients with recurrent GBM, pediatric patients, those with major comorbidities or contraindications to bevacizumab

Generalizability notes

Multicenter trial with 637 randomized patients
Central pathology confirmation enhances diagnostic accuracy

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 1 Methods

quote

randomized, double-blind, placebo-controlled trial

claim_id

stats_check.effect_sizes

locator

p. 1 Results

quote

hazard ratio for death in the bevacizumab group, 1.13

claim_id

practice_impact.bottom_line

locator

p. 1 Results

quote

First-line use of bevacizumab did not improve overall survival

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years